Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96591eb7f1de22f1be0631ee50d35214 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b3e6d8f05d9475eab2cebb5c85f9f80 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7151 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 |
filingDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c1859dc9753e5da9c1c837cf1548632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c38c3cd625e4f5206e00c03023bc1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded3ffbef394273bfea1226eb6919b70 |
publicationDate |
2021-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20210036621-A |
titleOfInvention |
Chimeric Cytokine Receptor Capable of Converting Immunosuppressive Signal to Immunostimmulatory Signal, Immune Cell Expressing the Same, and Anti-Cancer Use Thereof |
abstract |
The present invention relates to a chimeric cytokine receptor capable of converting an immunosuppressive signal into an immune activation signal, an immune cell expressing the same, and a pharmaceutical composition for the treatment of cancer comprising the immune cell as an active ingredient. The immune cells expressing the chimeric cytokine receptor of the present invention can exert a stronger cytotoxic effect against cancer by converting an immunosuppressive signal into an immune activation signal in a microtumor environment in which an immunosuppressive cytokine is present. The immune cells expressing the chimeric cytokine receptor of the present invention can be used as a cell therapy for cancer treatment. |
priorityDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |